Latest & greatest articles for diclofenac

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on diclofenac or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on diclofenac and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for diclofenac

41. Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam

Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Modelling therapeutic strategies in the treatment of osteoarthritis: an economic evaluation of meloxicam versus diclofenac and piroxicam Tavakoli M Record Status This is a critical abstract of an economic evaluation (...) that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac modified-release and piroxicam for 4 weeks, in the treatment of patients with osteoarthritis. The doses studied were 7.5 mg meloxicam once daily, 100 mg diclofenac

NHS Economic Evaluation Database.2003

42. A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac

A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac A pharmacoeconomic comparison of misoprostol/diclofenac with diclofenac Morant S V, Shield M J, Davey P G, MacDonald T M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology The misoprostol-diclofenac fixed combination preparation was compared with diclofenac and other prescribed nonsteroidal anti-inflammatory drugs (NSAIDs), to investigate the association between NSAIDs and admission to hospital for upper gastrointestinal (GI) haemorrhage and perforation and other upper GI events. Type of intervention Other: Secondary care. Economic study type Cost-effectiveness analysis. Study

NHS Economic Evaluation Database.2002

43. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis.

Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. 12501222 2002 12 26 2003 01 02 2015 11 19 1533-4406 347 26 2002 Dec 26 The New England journal of medicine N. Engl. J. Med. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. 2104-10 Current guidelines recommend that patients at risk for ulcer disease who require treatment for arthritis receive (...) nonsteroidal antiinflammatory drugs (NSAIDs) that are selective for cyclooxygenase-2 or the combination of a nonselective NSAID with a proton-pump inhibitor. We assessed whether celecoxib would be similar to diclofenac plus omeprazole in reducing the risk of recurrent ulcer bleeding in patients at high risk for bleeding. We studied patients who used NSAIDs for arthritis and who presented with ulcer bleeding. After their ulcers had healed, we randomly assigned patients who were negative for Helicobacter pylori to receive either

NEJM2002

44. Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain

Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Economic evaluation of nimesulide versus diclofenac in the treatment of osteoarthritis in France, Italy and Spain Tarricone R, Martelli E, Parazzini F, Darba J, Le Pen C, Rovira J Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of two drug therapies, nimesulide and diclofenac, for the treatment of osteoarthritis (OA). Both drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), which although beneficial in reducing pain and inflammation, may result in potentially serious consequences in terms

NHS Economic Evaluation Database.2001

45. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison.

Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. 10609815 2000 01 11 2000 01 11 2016 11 22 0140-6736 354 9196 1999 Dec 18-25 Lancet (London, England) Lancet Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. 2106-11 Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclo-oxygenase (COX), which leads to suppression of COX-1-mediated production of gastrointestinal (...) -protective prostaglandins. Gastrointestinal injury is a common outcome. We compared the efficacy, safety, and tolerability of long-term therapy with celecoxib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX inhibitor. 655 patients with adult-onset rheumatoid arthritis of at least 6 months' duration were randomly assigned oral celecoxib 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 weeks. Anti-inflammatory and analgesic activity and tolerability were assessed

Lancet2000

46. Single dose oral ibuprofen and diclofenac for postoperative pain.

Single dose oral ibuprofen and diclofenac for postoperative pain. BACKGROUND: Ibuprofen and diclofenac are two widely used non-steroidal anti-inflammatory (NSAID) analgesics. It is therefore important to know which drug should be recommended for postoperative pain relief. This review seeks to compare the relative efficacy of the two drugs, and also considers the issues of safety and cost. OBJECTIVES: To assess the analgesic efficacy of ibuprofen and diclofenac in single oral doses for moderate (...) pain of moderate to severe intensity, double-blind design, and random allocation to treatment groups which compared either ibuprofen or diclofenac with placebo. DATA COLLECTION AND ANALYSIS: Data were extracted by two independent reviewers, and trials were quality scored. Summed pain relief or pain intensity difference over four to six hours was extracted, and converted into dichotomous information yielding the number of patients with at least 50% pain relief. This was then used to calculate

Cochrane2000

47. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis

Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis Kristiansen I S, Kvien T K, Nord E Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of diclofenac and misoprostol for the treatment of patients with rheumatoid arthritis (RA). Type of intervention Treatment. Economic study type Cost-utility analysis. Study population The study population comprised patients with RA

NHS Economic Evaluation Database.1999

48. Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK

Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France, Italy and the UK Economic evaluation of meloxicam (7.5mg) versus sustained release diclofenac (100mg) treatment for osteoarthritis: a cross-national assessment for France (...) sustained release (SR) diclofenac (comparator, 100 mg/day). Type of intervention Treatment, palliative care. Economic study type Cost-effectiveness analysis. Study population The target population was that of patients with OA. Setting The setting was primary and secondary care. The economic analysis was conducted in France, Italy and the UK. Dates to which data relate Effectiveness evidence was from 1986 and an undated reference. Resource use dates ranged from 1989 to 1996. The price year was 1995-6

NHS Economic Evaluation Database.1997

49. The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis

The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis The cost effectiveness of diclofenac plus misoprostol compared with diclofenac monotherapy in patients with rheumatoid arthritis Al J A, Michel B C, Rutten F F Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Diclofenac plus misoprostol (50 mg + 200micrograms twice (tid) or three times (tid) daily) versusdiclofenac alone (50 mg bid or tid) in the prevention of nonsteroidal anti-inflammatory drug (NSAID)-induced ulcers in rheumatoid arthritis (RA) patients. Type

NHS Economic Evaluation Database.1996